Colorectal Cancer | Specialty

Financial Burden of Cancer Treatment Weighs Heavily on Patients

October 28th 2014

Nearly two-thirds of patients diagnosed with colorectal cancer report experiencing financial burden during their treatment, according to a study from the University of Michigan.

Fast Track Designation Granted to TAS-102 in mCRC

October 20th 2014

The FDA has granted a fast track designation to TAS-102 (tipiracil hydrochloride) as a treatment for patients with refractory metastatic colorectal cancer (mCRC), according to an announcement by Taiho Oncology, the company developing the drug in the United States.

Expanded 80405 Study Mutation Analysis Fails to Resolve Targeted Therapy Quandary in mCRC

September 30th 2014

All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.

Dr. Venook Discusses the Future of Colorectal Cancer Treatment

September 15th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the future of colorectal cancer treatment.

Ramucirumab Improves Survival in mCRC

September 12th 2014

The combination of ramucirumab and FOLFIRI significantly improved OS and PFS compared with chemotherapy alone as a second-line treatment for patients with mCRC.

BRAF-Mutated Colorectal Cancer: Early Frustrations and Future Optimism

August 22nd 2014

This review highlights that preclinical data and discusses several ongoing clinical trials that are leveraging this information to explore new therapeutic strategies in targeting BRAF-mutated colorectal cancer.

Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in CRC

August 19th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the efficacy and safety of panitumumab versus cetuximab as seen in the ASPECCT trial in colorectal cancer (CRC).

Dr. Venook Discusses the Results of the 80405 Trial

August 15th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial of targeted therapies administered in colorectal cancer.

FDA Approves First DNA-Based CRC Screening Tool

August 12th 2014

The FDA has approved the noninvasive stool-based DNA test Cologuard for the detection of colorectal cancer or cancer precursors in asymptomatic patients at average risk.

The Pivotal Role of Cooperative Group Trials

August 8th 2014

Managing Toxicities Associated With Regorafenib

August 8th 2014

Case Studies in Advanced Colorectal Cancer

August 8th 2014

Optimal Dosing of Regorafenib in CRC

August 8th 2014

Treatment Options for Advanced CRC

August 8th 2014

New Tactics Needed: Aspirin Studies in Colon Cancer Illustrate Shortcomings of Phase III Trial Orthodoxy

August 5th 2014

There is a tension in the air these days when it comes to the manner in which evidence-based oncology research should be conducted in this revolutionary era, and that tension is evident on the pages of peer-reviewed articles describing novel findings in clinical molecular oncology, in editorials discussing these studies, and in commentaries related to future approaches to discovery.

Dr. Bekaii-Saab Discusses an Analysis of Bevacizumab or Cetuximab for CRC

July 24th 2014

Tanios Bekaii-Saab, MD, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

Final Thoughts on Optimizing the Treatment of mCRC

July 23rd 2014

TAS-102 in Refractory mCRC

July 23rd 2014

Optimizing Treatment With Regorafenib in mCRC

July 23rd 2014

BRAF-Mutated Colorectal Cancer

July 23rd 2014